{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective as defined in Q1.", "method": "llm_batch", "batch_id": "batch_1_16488", "batch_size": 260, "batch_pos": 165, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "The segment does not contain high-potency verbs, potent metaphors, superlative negative nouns, or critical alert phrases.", "method": "llm_batch", "batch_id": "batch_2_16956", "batch_size": 260, "batch_pos": 165, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "The segment discusses future testing plans ('would begin in 2025'), not realised impact with a moderate verb + scale.", "method": "llm_batch", "batch_id": "batch_3_18272", "batch_size": 260, "batch_pos": 148, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 4, "answer": "no", "rationale": "The segment contains a statement about testing beginning, but no loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_12464", "batch_size": 260, "batch_pos": 143, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 5, "answer": "no", "rationale": "The segment reports testing timeline and does not contain an explicit calming cue.", "method": "llm_batch", "batch_id": "batch_5_14396", "batch_size": 260, "batch_pos": 142, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 6, "answer": "no", "rationale": "No minimiser or scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_11932", "batch_size": 260, "batch_pos": 133, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_14808", "batch_size": 260, "batch_pos": 131, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 8, "answer": "yes", "rationale": "States a timeline for future testing ('late-stage testing would begin in 2025'), relating to vaccine testing/development.", "method": "llm_batch", "batch_id": "batch_8_13156", "batch_size": 260, "batch_pos": 110, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
